ARCHIVES

Tasigna Shows High Response, PFS Benefit Compared to Gleevec in Phase III CML Study

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI’s Richard Kaplan named associate director, National Cancer Research Network of UK.

January 2, 2004

Clinical Trials Approved In August 2002 By NCI

September 27, 2002

Also Senate approves spending bill.

January 23, 2004

In Brief: Weinstein Names Permanent Director Of Columbia Comprehensive Center; Gottsman Heads Institute

February 8, 1985

Contract Awards: Texas Group Receives $472,000 To Monitor Asbestos Workers

August 23, 1974

Peter Shields Named Deputy Director At Ohio State

September 16, 2011